- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07906054
Ultra-high-performance Positron Emission Tomography (PET) of Synaptic Density, Reactive Astrogliosis and Tau in Alzheimer's Disease
Prospective in Vivo Ultra-high-performance PET Imaging of Synaptic Density, Reactive Astrogliosis and Tau Accumulation in Alzheimer's Disease, Healthy Controls and Centenarians and Relationship With Fluid Biomarkers
AIM: to investigate the relationship between synaptic density, tau and reactive astrogliosis in Alzheimer's disease (AD) versus healthy controls and centenarians.
DESIGN: this cross-sectional study will recruit patients with biomarker-proven AD, age- and sex-matched healthy controls as well as centenarians. All subjects will undergo a neuropsychological evaluation and ultra-high-performance PET imaging sessions with 18F-SynVesT-1 (synaptic density), 18F-MK6240 (tau) and 18F-SMBT-1 (reactive astrogliosis) as well as structural and diffusion MRI. Blood samples will be taken for the evaluation of blood-based biomarkers.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Lieux d'étude
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Belgique, 3000
- University Hospitals Leuven
-
Contact:
- Koen Van Laere, Prof.
- Numéro de téléphone: +3216343715
- E-mail: koen.vanlaere@uzleuven.be
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Patients with Alzheimer's disease will be recruited from the memory clinic of the University Hospitals Leuven (UZ Leuven). Centenarians will be recruited from the 100-plus study at UMC Amsterdam. Healthy controls will be recruited through internet advertisements.
La description
- Patients with Alzheimer's disease (AD)
Inclusion Criteria:
- Patient has a clinical diagnosis of biomarker proven AD (prodromal AD or dementia due to AD).
- Patient has an mini-mental state examination (MMSE) score of 15 or higher.
- Patient or legal representative is able to understand the patient information brochure and give written informed consent.
Exclusion Criteria:
- Patient has a history of any major other disease that may interfere with the investigations or make the subject unfit for participation according to the interpretation by the investigator.
- Patient is on anti-amyloid therapy.
- Patient has contra indications for magnetic resonance imaging (MRI).
- Patient is a current smoker.
- Patient is currently a user (including ''recreational use'') of any illicit drugs, including cannabis, or has a history of drug or alcohol abuse.
Healthy control participants
Inclusion Criteria:
- Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures
- Participant is judged to be in good health by the investigator on the basis of medical history, physical examination including vital signs, clinical laboratory test and urinalysis.
- No history or evidence of current major neurological, internal or psychiatric disorder, based on the medical assessment as described hereabove and neuropsychological assessment (Geriatric depression scale (GDS) and Beck's depression inventory (BDI)).
- A normal structural MRI scan with respect to the participant's age as assessed by expert radiologist.
- Participant has to be at least 40 years old
Exclusion Criteria:
- Participant has a history of any major disease that may interfere with the investigations or make the subject unfit for participation according to the interpretation by the investigator (especially diabetes mellitus, heart disease, liver and kidney disease, or most forms of cancer).
- Participant is a smoker or has a recent history of smoking.
- Participant has a history or evidence of psychiatric disease.
- Participant is currently a user (including ''recreational use'') of any illicit drugs, including cannabis, or has a history of drug or alcohol abuse.
- Participant has a contra-indication for MRI scanning.
- Participant suffers from claustrophobia or cannot tolerate confinement during PET-MRI scanning procedures. Subject cannot lie still for at least 30 minutes inside a scanner.
- Participant does not understand the study procedures.
- Participant is unwilling or unable to perform all of the study procedures or is considered unsuitable in any way by the principal investigator.
- Participant is pregnant or is breastfeeding.
Centenarians
Inclusion Criteria:
- Participant is included in the 100-plus study at Amsterdam UMC.
- Participant or legal representative is able to understand the information brochure and give written informed consent.
Exclusion Criteria:
- Participant has a history of any major disease that may interfere with the investigations or make the subject unfit for participation according to the interpretation by the investigator (especially diabetes mellitus, heart disease, liver and kidney disease, or most forms of cancer).
- Participant is a current smoker.
- Participant is currently a user (including ''recreational use'') of any illicit drugs, including cannabis, or has a history of drug or alcohol abuse.
- Participant has contra indications for MRI or cannot lie still in the scanner for 30 minutes.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: CASE_CONTROL
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Participants témoins en bonne santé
|
Ultra-high-performance positron emission tomography (PET) of monoamine oxidase B (MAO-B) using the radioligand 18F-SMBT-1 on the NeuroEXPLORER PET scanner. Ultra-high-performance positron emission tomography (PET) of synaptic vesicle glycoprotein 2A (SV2A, synaptic density) using the radioligand 18F-SynVesT-1 on the NeuroEXPLORER PET scanner. Ultra-high-performance positron emission tomography (PET) of tau neurofibrillary tangles using the radioligand 18F-MK6240 on the NeuroEXPLORER PET scanner. |
|
Patients with AD
|
Ultra-high-performance positron emission tomography (PET) of monoamine oxidase B (MAO-B) using the radioligand 18F-SMBT-1 on the NeuroEXPLORER PET scanner. Ultra-high-performance positron emission tomography (PET) of synaptic vesicle glycoprotein 2A (SV2A, synaptic density) using the radioligand 18F-SynVesT-1 on the NeuroEXPLORER PET scanner. Ultra-high-performance positron emission tomography (PET) of tau neurofibrillary tangles using the radioligand 18F-MK6240 on the NeuroEXPLORER PET scanner. |
|
Centenarians
|
Ultra-high-performance positron emission tomography (PET) of monoamine oxidase B (MAO-B) using the radioligand 18F-SMBT-1 on the NeuroEXPLORER PET scanner. Ultra-high-performance positron emission tomography (PET) of synaptic vesicle glycoprotein 2A (SV2A, synaptic density) using the radioligand 18F-SynVesT-1 on the NeuroEXPLORER PET scanner. Ultra-high-performance positron emission tomography (PET) of tau neurofibrillary tangles using the radioligand 18F-MK6240 on the NeuroEXPLORER PET scanner. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
The correlation between tau, synaptic density and reactive astrogliosis
Délai: Baseline
|
Mediation and correlation analyses will be performed to investigate the correlation between tau, synaptic density and reactive astrogliosis PET measures as quantified by standardized uptake value ratios (SUVR). |
Baseline
|
|
Changes in synaptic density, tau and reactive astrolgiosis between AD patients, controls and centenarians
Délai: Baseline
|
Synaptic density, tau and reactive astrolgiosis PET measures, as quantified by standardized uptake value ratios (SUVR), will be compared across the three different groups: patients with AD, healthy control participants and centenarians. |
Baseline
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Correlation of synaptic density, tau and reactive astrogliosis with diffusion MRI
Délai: Baseline
|
The correlation of synaptic density, tau and reactive astrolgiosis PET, as quantified by standardized uptake value ratios (SUVR) in typical regions, with diffusion MRI metrics (fibre density and fibre cross-section) in the connecting white matter bundles will be assessed. |
Baseline
|
|
Correlation of synaptic density, tau and reactive astrogliosis with blood-based biomarkers
Délai: Baseline
|
The correlation of synaptic density, tau and reactive astrogliosis PET measures, as quantified by standardized uptake value ratios (SUVR), with blood-based markers of synaptic integrity and reactive astrogliosis will be assessed. |
Baseline
|
|
Correlation of synaptic density, tau and reactive astrogliosis with cognitive performance
Délai: Baseline
|
The correlation of synaptic density, tau and reactive astrolgiosis PET measures, as quantified by standardized uptake value ratios (SUVR), with neuropsychological test scores will be assessed. |
Baseline
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- S72313
- SAO-FRA20250007 (Autre subvention/numéro de financement: Belgian Alzheimer Research Foundation)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .